Cure8 research brief
This study suggests a plant extract (Macleaya cordata) and its component sanguinarine reduced inflammation and improved colitis signs in mice by changing gut bacteria and macrophage activation — mechanisms relevant to ulcerative colitis. That could point to new research directions for IBD therapies.
Researchers studying IBD mechanisms, microbiome interventions, or immunomodulators; clinicians following preclinical therapeutic development; patients and caregivers interested in emerging laboratory research (not clinical evidence).
This lab and mouse study tested an extract from the plant Macleaya cordata (MCE) and its two active components, sanguinarine and chelerythrine, in a dextran sulfate sodium (DSS) model of colitis. In mice, MCE reduced disease-associated pathology and shifted gut bacteria (lower Streptococcus, higher Dubosiella and Akkermansia).
Flow cytometry showed fewer pro-inflammatory M1 macrophages and more M2 macrophages in colon and spleen. In cell experiments, sanguinarine inhibited NF-κB activation and reactive oxygen species in LPS-stimulated macrophages and had stronger anti-colitis effects than chelerythrine in the reported assays.
Key details This report is an experimental preclinical (mouse and cell) study published in the journal Antioxidants. It describes changes in gut microbiota composition, macrophage polarization, and cellular inflammatory signaling after treatment with the plant extract or its components. It does not report clinical trial data in people.
Practical takeaways These findings are preliminary and support further research into MCE and sanguinarine as potential anti-inflammatory agents that act on gut microbes and macrophage responses. They do not establish safety or effectiveness in people with ulcerative colitis, nor do they justify using these extracts as treatment without clinical testing.
this is a preclinical study (DSS mouse model and macrophage cell experiments) published in a journal article abstract. Results in animals and cells often do not translate directly to benefits or safety in humans. Additional studies including controlled clinical trials would be needed before any clinical use.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: the Science and Technology Program of Gansu Province, award 26YFNA028; the Science and Technology Program of Gansu Province, award 26CXNA054; National Natural Science Foundation of China, award U21A20262; award U21A20262
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research suggests a new, preclinical microbiome- and metabolite-based pathway (APA-1 → THDCA → TGR5/cAMP/PKA → NLRP3) that reduced inflammation in a mouse model of ulcerative colitis, which could guide future...
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
The study identifies a new compound that reduced colitis severity in mice by acting on macrophage NF-κB signaling, lowering MMP7, improving epithelial barrier markers, and altering the gut microbiome — mechanisms...
